Publications by authors named "Marco Delsante"

Renal prognosis in light-chain amyloidosis (AL) is determined by categorizing patients into three renal stages at diagnosis and assessing Renal Response or Renal Progression following chemotherapy after 6 months. We evaluated, in a test (N=1935) cohort of patients with renal AL amyloidosis who were followed for a median of 95 months, a modified 4-stage model where Renal Stage 2 was sub-categorized according to preserved (2A) or reduced (2B) estimated Glomerular Filtration Rate (eGFR). A hybrid model for evaluation of Renal Progression was also introduced, using an eGFR cut-off of 30ml/min/1.

View Article and Find Full Text PDF

We report on the first case of a dual-kidney transplant recipient diagnosed with a metastatic BK polyomavirus-positive clear renal cell carcinoma with sarcomatoid features, which caused extensive vena cava thrombosis. The patient was successfully treated with the immune checkpoint inhibitors (ICIs) ipilimumab plus nivolumab and continued immunosuppression with tacrolimus, mycophenolate, and steroids. He received ICIs despite the presence of graft dysfunction due to transplant glomerulopathy.

View Article and Find Full Text PDF

Aberrant O-glycosylation of the IgA1 hinge region is a characteristic finding in patients with IgA nephropathy (IgAN) and is thought to contribute to immune-complex formation and kidney injury. Other studies have suggested that abnormalities in mucosal immunity and lymphocyte homing are major contributors to disease. We identified a family with IgAN segregating a heterozygous predicted loss-of-function (LOF) variant in GALNT14, the gene encoding N-acetylgalactosaminyltransferase 14, one of the enzymes involved in mucin-type protein O-glycosylation.

View Article and Find Full Text PDF

Membranous nephropathy (MN) is a kidney disease characterized by thickening of the glomerular basement membrane due to immune complex deposition, often leading to nephrotic syndrome and potentially progressing to end-stage renal disease. Traditional treatments, including corticosteroids and immunosuppressive agents, have significant side-effects and variable efficacy. Recently, obinutuzumab, a fully humanized monoclonal antibody targeting CD20, has emerged as a promising therapeutic option for MN.

View Article and Find Full Text PDF
Article Synopsis
  • * Despite the known association with complement activation, evidence shows that microvascular inflammation and endothelial damage can occur independently of this system, particularly in late AMR (>6 months post-transplant).
  • * The review discusses differences in mechanisms and clinical features between early and late AMR, suggesting that treatment strategies should reflect these variations in underlying inflammatory processes and complement activation levels.
View Article and Find Full Text PDF
Article Synopsis
  • Antibody-mediated rejection (AMR) is a major cause of long-term kidney transplant failure, even with advancements in immunosuppressive therapies.
  • * A case is described where late active AMR progressed to severe chronic active AMR, treated with a multidrug approach.
  • * The current treatment options and understanding of AMR, including the role of donor-specific antibodies and various therapeutic strategies, highlight a need for improved guidelines based on stronger evidence.*
View Article and Find Full Text PDF
Article Synopsis
  • Gastrointestinal severe adverse events like ulceration and perforation have been linked to polystyrene sulfonate and sevelamer, especially in patients with chronic kidney disease, but the exact cause is unclear.* -
  • A meta-analysis of existing research found that polystyrene sulfonate is significantly more likely to cause severe issues such as necrosis or perforation compared to sevelamer (p < 0.001).* -
  • The findings indicate that while sevelamer may cause inflammation or ulceration, polystyrene sulfonate is more strongly associated with severe outcomes, including a higher risk of death (p < 0.001).*
View Article and Find Full Text PDF

Key Points: We conducted a clinical, genetic, and pathological analysis on 64 cases from 39 families with TRPC6-associated podocytopathy (TRPC6-AP). Analysis of 37,542 individuals excluded a major contribution of loss-of-function variants to TRPC6-AP, legitimating current drug discovery approaches. This study identifies key features of disease that can help intervention studies design and suggests similarities between TRPC6-AP and primary FSGS.

View Article and Find Full Text PDF

Microvascular inflammation (MVI), defined as the presence of glomerulitis and/or peritubular capillaritis, is the key histological lesion of anti-HLA donor-specific antibodies (DSA)-related antibody mediated rejection, but recently other possible mechanisms of MVI have emerged. However, except for peritubular capillary C4d deposition that is more frequently observed in the presence of anti-HLA-DSA, histological features are similar regardless of MVI origin. Therefore, accurately describing patterns of MVI may help differentiate etiologies and drive therapeutic choices.

View Article and Find Full Text PDF

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. IgAN causes end-stage kidney disease (ESKD) in 30-40% of all cases. The activation of the complement system by pathological circulating IgAs, which is often associated with low serum C3 levels (LowC3), seems to play a crucial role.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines the necessity of treatment with intravenous steroids versus clinical follow-up for kidney transplant recipients diagnosed with "borderline" acute T-cell mediated rejection (TCMR).
  • Researchers followed 59 patients over 12 months, comparing the groups receiving treatment (TRT) and those with simple clinical follow-up (F-UP), measuring trends in renal function through estimated glomerular filtration rate (eGFR).
  • Results showed that while the TRT group initially had lower kidney function, they reached comparable eGFR levels to the F-UP group after 12 months, indicating that treatment may be beneficial in cases with indication biopsies.
View Article and Find Full Text PDF

Chronic kidney disease progresses through the replacement of functional tissue compartments with fibrosis, a maladaptive repair process. Shifting kidney repair toward a physiologically intact architecture, rather than fibrosis, is key to blocking chronic kidney disease progression. Much research into the mechanisms of fibrosis is performed in rodent models with less attention to the human genetic context.

View Article and Find Full Text PDF

Background: Since primary membranous nephropathy is a heterogeneous disease with variable outcomes and multiple possible therapeutic approaches, all 13 Nephrology Units of the Italian region Emilia Romagna decided to analyze their experience in the management of this challenging glomerular disease.

Methods: We retrospectively studied 205 consecutive adult patients affected by biopsy-proven primary membranous nephropathy, recruited from January 2010 through December 2017. The primary outcome was patient and renal survival.

View Article and Find Full Text PDF

The use of dabigatran in patients with non-valvular atrial fibrillation (AF) has widely increased in the last decades, due to its positive effects in terms of safety/efficacy. However, because of the risk of major bleeding, a great degree of attention has been suggested in elderly patients with multiple comorbidities. Notably, dabigatran mainly undergoes renal elimination and dose adjustment is recommended in patients with Chronic Kidney Disease (CKD).

View Article and Find Full Text PDF

Retinitis pigmentosa (RP) is the most common inherited retinal disease (IRD) and is characterized by photoreceptor degeneration and progressive vision loss. We report 4 patients presenting with RP from 3 unrelated families with variants in TBC1D32, which to date has never been associated with an IRD. To validate TBC1D32 as a putative RP causative gene, we combined Xenopus in vivo approaches and human induced pluripotent stem cell-derived (iPSC-derived) retinal models.

View Article and Find Full Text PDF

Background & Aims: Sarcopenia is prevalent in patients with end-stage kidney disease (ESKD) on hemodialysis (HD), and is associated with poor outcomes, while obesity may be protective. Sarcopenic obesity is associated with increased frailty, morbidity and mortality in the general population. Myosteatosis, i.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigated the impact of the modified Oxford classification of MEST-C components on graft failure in kidney transplant recipients with IgAN, focusing on a North American cohort to validate previous findings from an Asian population.
  • - It analyzed 171 transplant recipients, discovering that recurrent IgAN significantly heightened the risk of graft failure, especially in younger patients, and that a higher MEST-C score was associated with increased failure risk.
  • - The results showed consistency with the Asian cohort's findings, suggesting that the MEST-C score could serve as a valuable tool in diagnosing and managing recurrent IgAN in kidney transplant patients.
View Article and Find Full Text PDF

Introduction: Proliferative lupus nephritis (LN) progresses to end-stage kidney disease (ESKD) in roughly 10% of the cases despite treatment. Other than achieving <0.8 g/24h proteinuria at 12 months after treatment, early biomarkers predicting ESKD or death are lacking.

View Article and Find Full Text PDF
Article Synopsis
  • Polycystic kidney diseases (PKD) are significant contributors to chronic kidney disease, with autosomal dominant PKD (ADPKD) being the most prevalent form, while a new atypical form caused by DNAJB11 mutations has been identified.
  • A study compared 27 patients with DNAJB11-PKD to 42 typical ADPKD patients, revealing that DNAJB11-PKD patients had smaller kidneys and cysts, and progressed more slowly to end-stage kidney disease.
  • The findings indicated that DNAJB11-PKD presents unique clinical features, such as older age and higher rates of type 2 diabetes and kidney stones, suggesting that it should be classified separately from
View Article and Find Full Text PDF
Article Synopsis
  • The study explores the impact of COVID-19 on patients with glomerulonephritis (GN) by analyzing data from 125 GN patients and 83 non-GN controls, focusing on kidney health outcomes over an average follow-up period of 6.4 months.
  • Findings indicate that there were no significant differences in mortality or acute kidney injury (AKI) between GN patients and controls, with pre-COVID-19 kidney function (eGFR) being a critical predictor of AKI risk.
  • GN patients show a lower likelihood of recovering kidney function post-AKI compared to controls, particularly those with shorter GN diagnoses or higher protein levels, suggesting a need for careful monitoring of these patients after COVID-19.
View Article and Find Full Text PDF